Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Atezolizumab
Atezolizumab in · 1 trial · 1 indication
Calculated as the percentage of participants alive and without disease progression, as assessed by the Investigator using RECIST v1.1
he number of patients with AEs and SAEs, changes in laboratory values, vital signs, ECGs, and results of physician examinations graded according to the CTCAE v 5.0.
| Arm | Type | Description |
|---|---|---|
| Atezo+DCvac | EXPERIMENTAL | \- Induction (4 cycles, every 3 weeks): Carboplatin area under the curve (AUC) 5 (5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle) Atezolizumab, 1200 mg administered intravenously every 3 weeks on day 1 of each cycle) \- Maintenance (only patients without PD after 4 induction cycles, up to PD): Atezolizumab iv (1200 mg/IV on day 1 every 3 weeks) DCV intradermally (max. 6 doses) on weeks 1, 3, 6, 9, 21, 33. |
| Name | Type | Description |
|---|---|---|
| Atezolizumab 1200 mg in 20 ML Injection | DRUG | \- Induction (4 cycles, every 3 weeks): Atezolizumab, 1200 mg administered intravenously every 3 weeks on day 1 of each cycle) \- Maintenance (only patients without PD after 4 induction cycles, up to PD): Atezolizumab iv (1200 mg/IV on day 1 every 3 weeks) |
| ADC Vaccine | BIOLOGICAL | \- Maintenance (only patients without PD after 4 induction cycles, up to PD): DCV intradermally (max. 6 doses) on weeks 1, 3, 6, 9, 21, 33. |
| Carboplatin | DRUG | \- Induction (4 cycles, every 3 weeks): Carboplatin AUC 5 (5 mg per milliliter per minute, administered intravenously on day 1 of each cycle) and etoposide (100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle) |
Inclusion Criteria: 1. Histological diagnosis of extensive-stage small cell lung cancer (ES-SCLC). Unequivocally confirmed diagnosis of SCLC by histology preferably including the presence of neuroendocrine features by immunohistochemistry. 2. Centrally confirmed tumor tissue viability for vaccine p...
Atezolizumab is an investigational oncology drug being studied for extensive-stage small cell lung cancer, pleural mesothelioma malignant advanced, lymphoma, squamous cell carcinoma of the head and neck, acute myeloid leukemia, carcinoma, and small cell lung cancer. It is currently in Phase 1 clinical development.
Atezolizumab is a monoclonal antibody, classified as a -mab antibody. It is being developed by Roche Holding AG for use in multiple oncology indications, including lung cancer and lymphoma.
Atezolizumab is developed by Roche Holding AG, traded on the OTC market under the ticker RHHBY. The drug is currently in Phase 1 clinical trials for various oncology indications.
Atezolizumab is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. It is being studied across multiple cancer types, including small cell lung cancer and lymphoma.
Atezolizumab has been studied in several clinical trials. One completed trial, NCT02729896, evaluated it in relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma. Another completed trial, NCT03038100, studied it in ovarian cancer. A Phase 2 trial, NCT04677504, examined it in advanced biliary tract cancer.
Yes, Atezolizumab is also known as Atezolizumab 1200 MG/40mL Intravenous Solution. This alternative name refers to the drug's formulation and concentration for intravenous administration.